1. Home
  2. RDWR vs KALV Comparison

RDWR vs KALV Comparison

Compare RDWR & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Radware Ltd.

RDWR

Radware Ltd.

HOLD

Current Price

$26.27

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$19.06

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDWR
KALV
Founded
1996
N/A
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2000
2014

Fundamental Metrics

Financial Performance
Metric
RDWR
KALV
Price
$26.27
$19.06
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$32.50
$32.60
AVG Volume (30 Days)
176.3K
1.1M
Earning Date
05-07-2026
07-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$50,000,000.00
Revenue This Year
$10.65
$185.42
Revenue Next Year
$8.62
$59.23
P/E Ratio
$59.76
N/A
Revenue Growth
N/A
495.66
52 Week Low
$21.34
$9.83
52 Week High
$30.57
$21.31

Technical Indicators

Market Signals
Indicator
RDWR
KALV
Relative Strength Index (RSI) 53.28 50.16
Support Level $23.64 $14.66
Resistance Level $28.10 $21.31
Average True Range (ATR) 1.07 1.15
MACD 0.04 -0.22
Stochastic Oscillator 58.56 17.32

Price Performance

Historical Comparison
RDWR
KALV

About RDWR Radware Ltd.

Radware Ltd is a provider of application security and delivery solutions for multi-cloud environments. Its solutions secure the digital experience by providing infrastructure, application, and network protection and availability services to companies globally. Its solutions are deployed by, among others, enterprises, carriers, and cloud service providers. The company offers solutions in two main categories: Products offers a range of cloud-based security-as-a-service subscriptions, on-premises hardware and software products, and product subscriptions (or a combination of these) to customers; and Services offers managed services, professional services, technical support and training and certification to customers and partners.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: